Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed
Ovarian cancer, one of the most common gynecological malignancies, is characterized by high mortality and poor prognosis. Cytoreductive surgery and chemotherapy remain the mainstay of ovarian cancer treatment, and most women experience recurrence after standard care therapies. There is compelling ev...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1034903/full |
| _version_ | 1811229443285319680 |
|---|---|
| author | Xiaoyi Hu Ce Bian Xia Zhao Tao Yi |
| author_facet | Xiaoyi Hu Ce Bian Xia Zhao Tao Yi |
| author_sort | Xiaoyi Hu |
| collection | DOAJ |
| description | Ovarian cancer, one of the most common gynecological malignancies, is characterized by high mortality and poor prognosis. Cytoreductive surgery and chemotherapy remain the mainstay of ovarian cancer treatment, and most women experience recurrence after standard care therapies. There is compelling evidence that ovarian cancer is an immunogenic tumor. For example, the accumulation of tumor-infiltrating lymphocytes is associated with increased survival, while increases in immunosuppressive regulatory T cells are correlated with poor clinical outcomes. Therefore, immunotherapies targeting components of the tumor microenvironment have been gradually integrated into the existing treatment options, including immune checkpoint blockade, adoptive cell therapy, and cancer vaccines. Immunotherapies have changed guidelines for maintenance treatment and established a new paradigm in ovarian cancer treatment. Despite single immunotherapies targeting DNA repair mechanisms, immune checkpoints, and angiogenesis bringing inspiring efficacy, only a subset of patients can benefit much from it. Thus, the multi-immunotherapy investigation remains an active area for ovarian cancer treatment. The current review provides an overview of various clinically oriented forms of multi-immunotherapy and explores potentially effective combinational therapies for ovarian cancer. |
| first_indexed | 2024-04-12T10:15:57Z |
| format | Article |
| id | doaj.art-55e26e438bef409c961a256626c6ba39 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-12T10:15:57Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-55e26e438bef409c961a256626c6ba392022-12-22T03:37:13ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-10-011310.3389/fimmu.2022.10349031034903Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bedXiaoyi HuCe BianXia ZhaoTao YiOvarian cancer, one of the most common gynecological malignancies, is characterized by high mortality and poor prognosis. Cytoreductive surgery and chemotherapy remain the mainstay of ovarian cancer treatment, and most women experience recurrence after standard care therapies. There is compelling evidence that ovarian cancer is an immunogenic tumor. For example, the accumulation of tumor-infiltrating lymphocytes is associated with increased survival, while increases in immunosuppressive regulatory T cells are correlated with poor clinical outcomes. Therefore, immunotherapies targeting components of the tumor microenvironment have been gradually integrated into the existing treatment options, including immune checkpoint blockade, adoptive cell therapy, and cancer vaccines. Immunotherapies have changed guidelines for maintenance treatment and established a new paradigm in ovarian cancer treatment. Despite single immunotherapies targeting DNA repair mechanisms, immune checkpoints, and angiogenesis bringing inspiring efficacy, only a subset of patients can benefit much from it. Thus, the multi-immunotherapy investigation remains an active area for ovarian cancer treatment. The current review provides an overview of various clinically oriented forms of multi-immunotherapy and explores potentially effective combinational therapies for ovarian cancer.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1034903/fullovarian cancerimmunotherapymulti-immunotherapyimmune checkpoint inhibitoradoptive cell therapycancer vaccine |
| spellingShingle | Xiaoyi Hu Ce Bian Xia Zhao Tao Yi Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed Frontiers in Immunology ovarian cancer immunotherapy multi-immunotherapy immune checkpoint inhibitor adoptive cell therapy cancer vaccine |
| title | Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed |
| title_full | Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed |
| title_fullStr | Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed |
| title_full_unstemmed | Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed |
| title_short | Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed |
| title_sort | efficacy evaluation of multi immunotherapy in ovarian cancer from bench to bed |
| topic | ovarian cancer immunotherapy multi-immunotherapy immune checkpoint inhibitor adoptive cell therapy cancer vaccine |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1034903/full |
| work_keys_str_mv | AT xiaoyihu efficacyevaluationofmultiimmunotherapyinovariancancerfrombenchtobed AT cebian efficacyevaluationofmultiimmunotherapyinovariancancerfrombenchtobed AT xiazhao efficacyevaluationofmultiimmunotherapyinovariancancerfrombenchtobed AT taoyi efficacyevaluationofmultiimmunotherapyinovariancancerfrombenchtobed |